Laxer R M, Silverman E D, St-Cyr C, Tran M T, Lingam G
Division of Immunology and Rheumatology, Hospital for Sick Children, Toronto, Ontario, Canada.
Clin Ther. 1988;10(4):381-7.
The safety of naproxen suspension was assessed in an open study in children with juvenile rheumatoid arthritis. Fifty-eight patients aged 1 to 13 (mean, 4.5 years) were studied. Based on the patient's condition, naproxen was prescribed at dosages ranging from 9 to 20 mg/kg/day. Follow-up assessments were made during regular clinic visits, as often as deemed necessary by the physician. Forty-four patients completed a minimum of six months' treatment. One patient was lost to follow up and 13 were withdrawn early: three because of unsatisfactory therapeutic response, one because of disease remission, five because of taste complaints, and four because of other side effects. The side effects were mostly gastrointestinal and were mild to moderate in severity. Investigators' subjective evaluations indicated that 84% of the patients who completed six months' treatment had good or excellent therapeutic responses at termination. The study results demonstrated that naproxen suspension is a well-tolerated anti-inflammatory agent for young children with juvenile rheumatoid arthritis.
在一项针对幼年类风湿性关节炎患儿的开放性研究中评估了萘普生混悬液的安全性。研究了58名年龄在1至13岁（平均4.5岁）的患者。根据患者病情，萘普生的处方剂量为9至20毫克/千克/天。在定期门诊就诊时进行随访评估，随访频率由医生视情况而定。44名患者完成了至少六个月的治疗。1名患者失访，13名患者提前退出：3名因治疗反应不满意，1名因疾病缓解，5名因味觉不适，4名因其他副作用。副作用大多为胃肠道反应，严重程度为轻度至中度。研究者的主观评估表明，完成六个月治疗的患者中，84%在治疗结束时具有良好或优异的治疗反应。研究结果表明，萘普生混悬液对于患有幼年类风湿性关节炎的幼儿是一种耐受性良好的抗炎药。
